Precision BioSciences’ (DTIL) “Buy” Rating Reiterated at HC Wainwright

Precision BioSciences (NASDAQ:DTIL – Get Rating)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Wednesday, Benzinga reports. They currently have a $17.00 target price on the stock. HC Wainwright also issued estimates for Precision BioSciences’ FY2026 earnings at $0.37 EPS.

Several other research analysts also recently commented on DTIL. BMO Capital Markets downgraded Precision BioSciences from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $7.00 to $4.00 in a research note on Monday. BTIG Research cut their target price on Precision BioSciences to $6.00 in a research note on Tuesday, November 15th.

Precision BioSciences Stock Down 1.2 %

Shares of NASDAQ DTIL opened at $0.89 on Wednesday. Precision BioSciences has a 52 week low of $0.86 and a 52 week high of $3.64. The business has a 50-day simple moving average of $1.17 and a two-hundred day simple moving average of $1.29. The company has a quick ratio of 3.34, a current ratio of 3.34 and a debt-to-equity ratio of 0.37. The company has a market cap of $98.88 million, a P/E ratio of -0.63 and a beta of 1.45.

Institutional Trading of Precision BioSciences

A number of large investors have recently modified their holdings of DTIL. Balyasny Asset Management LLC boosted its position in shares of Precision BioSciences by 70.1% during the 3rd quarter. Balyasny Asset Management LLC now owns 19,333 shares of the company’s stock valued at $25,000 after acquiring an additional 7,967 shares during the last quarter. Quantbot Technologies LP boosted its position in shares of Precision BioSciences by 3,915.4% during the 3rd quarter. Quantbot Technologies LP now owns 20,077 shares of the company’s stock valued at $26,000 after acquiring an additional 19,577 shares during the last quarter. Cetera Investment Advisers boosted its position in shares of Precision BioSciences by 79.1% during the 2nd quarter. Cetera Investment Advisers now owns 20,381 shares of the company’s stock valued at $33,000 after acquiring an additional 9,000 shares during the last quarter. Platform Technology Partners bought a new stake in shares of Precision BioSciences during the 3rd quarter valued at about $33,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Precision BioSciences during the 1st quarter valued at about $34,000. Institutional investors own 50.50% of the company’s stock.

About Precision BioSciences

(Get Rating)

Precision BioSciences, Inc is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases.